SCHEMBL14399

SCHEMBL14399

CB1OC(C)(C)C(C)(C)O1

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.38
LAP3 P28838 2/20 0.38
APLNR P35414 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20625972 0.85
SCHEMBL12308559 0.80
SCHEMBL16306680 0.77
SCHEMBL19698899 0.77
SCHEMBL12719694 0.77
SCHEMBL17533126 0.77
SCHEMBL17190703 0.74 ANPEP (0.33) ANPEPLAP3APLNR
SCHEMBL341854 0.73 ANPEP (0.33) ANPEPLAP3
SCHEMBL19355225 0.71
SCHEMBL15916667 0.70 ANPEP (0.40) ANPEPLAP3APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3668 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409882-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-08-09 US claimed
US-20150307472-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 US claimed
EP-2888244-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-07-01 EP claimed
CN-104583198-A Novel pyridine derivatives HOFFMANN LA ROCHE 2015-04-29 CN claimed
WO-2014029722-A1 NOVEL PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO claimed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
US-20260138998-A1 GLP-1 RECEPTOR AGONISTS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-05-21 US disclosed
US-12590108-B2 Boracic acid compound PHAENO THERAPEUTICS CO., LTD (CN) 2026-03-31 US disclosed
US-12583824-B2 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity GENZYME CORPORATION (US) 2026-03-24 US disclosed
EP-4667054-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2025-12-24 EP disclosed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
US-20250304582-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2025-10-02 US disclosed
US-20030166615-A1 Protein kinase and phosphatase inhibitors and methods for designing them RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed
WO-2003035621-A1 PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2003-05-01 WO disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
WO-2003002118-A1 SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-01-09 WO disclosed
EP-1147214-A1 A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2001-10-24 EP disclosed
WO-2000042213-A1 A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2000-07-20 WO disclosed
US-4537773-A α-Aminoboronic acid derivatives E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-08-27 US disclosed